Bayer Aktiengesellschaft / Legal Matter 03.03.2008 Release of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Court Decides against the Companys Yasmin® Patent Leverkusen, Germany, March 3, 2008 On March 3, 2008, the US District Court for the District of New Jersey ruled against the validity of Bayer Schering Pharmas 531 patent for the companys oral contraceptive Yasmin, the result of a patent challenge by generic manufacturer Barr Laboratories. Bayer disagrees with the courts decision and will consider its legal options in this regard. The company will continue to vigorously defend its intellectual property. Bayer is currently evaluating the impact of the courts decision on another product of the companys line of oral contraceptives, the oral contraceptive YAZ which was approved for marketing by the US FDA and launched in 2006. However, regardless of the outcome of todays court decision Bayer retains marketing exclusivity for YAZ as an oral contraceptive in the US until March 16, 2009. No generic manufacturer can lawfully market a generic version of YAZ for an oral contraceptive indication until after March 16, 2009. The company has now slightly adjusted the subgroups margin target and plans to improve the EBITDA margin before special items of Bayer HealthCare toward 27 percent in 2008, from 25.6 percent in 2007. However, the margin target of around 28 percent for 2009 remains unchanged. Sales of Yasmin in the US amounted to EUR 321 million in 2007. --------------------------------------------------------------------------- Information and Explaination of the Issuer to this News: Forward-Looking Statements This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayers public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Contacts at Bayer AG, Investor Relations: Dr. Alexander Rosar (+49-214-30-81013) Dr. Juergen Beunink (+49-214-30-65742) Peter Dahlhoff (+49-214-30-33022) Ilia Kürten (+49-214-30-35426) Ute Menke (+49-214-30-33021) Judith Nestmann (+49-214-30-66836) Dr. Olaf Weber (+49-214-30-33567) Contact: Herr Peter Dahlhoff, Bayer AG, Investor Relations, Tel.: 0214-30-33022, e-mail: peter.dahlhoff@bayer-ag.de, Fax: 0214-30-96-33022 DGAP 03.03.2008 --------------------------------------------------------------------------- Language: English Issuer: Bayer Aktiengesellschaft Gebäude W 11 51368 Leverkusen Deutschland Phone: +49 (0)21430-1 Fax: +49 (0)21430-66328 E-mail: alexander.rosar.ar1@bayer-ag.de Internet: www.bayer-ag.de ISIN: DE0005752000 WKN: 575200 Indices: DAX,, EURO STOXX 50 Listed: Regulierter Markt in Berlin, Frankfurt (Prime Standard), Hannover, Düsseldorf, Stuttgart, München, Hamburg; Terminbörse EUREX; Foreign Exchange(s) London, Madrid, Tokyo, SWX End of News DGAP News-Service ---------------------------------------------------------------------------
DGAP-Adhoc: Bayer AG: Court Decides against the Companys Yasmin® Patent
| Source: EQS Group AG